Press releases

New tool available to assist in the treatment of peripheral arterial disease.

Clinical presentations will provide new insights on Boston Scientific research in cardiovascular disease, including aortic valve disease and atrial fibrillation.

Extensive sales resources, distribution network and service capabilities are expected to enable Boston Scientific to reach substantially more accounts, customers and patients in Japan.

The next advance in durable polymer stent technology from Boston Scientific is now available in Europe and other select geographies.

Organizations team up to raise awareness and make a call to action for European governments to develop comprehensive chronic pain treatment programs.

“I am confident we are taking the critical steps that are needed to return our company to long-term growth,” said president and CEO Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q4 and FY ended December 31. Learn how to tune in.

International, multi-center study focuses on patients with paroxysmal atrial fibrillation.

Company begins evaluation of its next generation pacing leads.

Close the Gap initiative urges fans to learn their risk factors for heart disease.